ARVN Insider Trading

Insider Ownership Percentage: 5.23%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $769,402.28

Arvinas Insider Trading History Chart

This chart shows the insider buying and selling history at Arvinas by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Arvinas Share Price & Price History

Current Price: $9.21
Price Change: Price Increase of +0.16 (1.77%)
As of 04/28/2025 05:00 PM ET

This chart shows the closing price history over time for ARVN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$9.21Closing price on 04/28/25:

SEC Filings (Institutional Ownership Changes) for Arvinas (NASDAQ:ARVN)

95.19% of Arvinas stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ARVN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$554kbought$558ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50M$0$50MTotal InflowsTotal Outflows
Arvinas logo
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Read More on Arvinas

Today's Range

Now: $9.21
Low: $9.07
High: $9.41

50 Day Range

MA: $10.39
Low: $6.19
High: $18.37

52 Week Range

Now: $9.21
Low: $5.94
High: $37.38

Volume

1,292,522 shs

Average Volume

1,142,039 shs

Market Capitalization

$633.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.3

Who are the company insiders with the largest holdings of Arvinas?

Arvinas' top insider investors include:
  1. John G Houston (CEO)
  2. Sean A Cassidy (CFO)
  3. Ian Taylor (Insider)
  4. Noah Berkowitz (Insider)
  5. Ronald Peck (Insider)
  6. David K Loomis (CAO)
Learn More about top insider investors at Arvinas.

Who are the major institutional investors of Arvinas?

Arvinas' top institutional shareholders include:
  1. Rhumbline Advisers — 0.13%
  2. Assenagon Asset Management S.A. — 0.12%
  3. Hennion & Walsh Asset Management Inc. — 0.09%
  4. IMC Chicago LLC — 0.00%
  5. Exchange Traded Concepts LLC — 0.02%
  6. Teacher Retirement System of Texas — 0.02%
Learn More about top institutional investors of Arvinas stock.

Which major investors are selling Arvinas stock?

Within the last quarter, ARVN stock was sold by these institutional investors:
  1. Assenagon Asset Management S.A.
  2. Hennion & Walsh Asset Management Inc.
  3. Teacher Retirement System of Texas
Within the last year, company insiders that have sold Arvinas company stock include:
  1. John G Houston (CEO)
  2. Sean A Cassidy (CFO)
  3. Ian Taylor (Insider)
  4. Noah Berkowitz (Insider)
Learn More investors selling Arvinas stock.

Which major investors are buying Arvinas stock?

Within the last quarter, ARVN stock was acquired by institutional investors including:
  1. IMC Chicago LLC
  2. Allspring Global Investments Holdings LLC
  3. Exchange Traded Concepts LLC
  4. GAMMA Investing LLC
  5. Rhumbline Advisers